The aggregate index of systemic inflammation (AISI): a novel predictor for hypertension

Objective Inflammation plays an important role in the pathophysiology of hypertension (HTN). Aggregate index of systemic inflammation (AISI), as a new inflammatory and prognostic marker has emerged recently. Our goal was to determine whether there was a relationship between HTN and AISI. Methods We analyzed patients with HTN from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2018. The primary end point was cardiovascular mortality. A total of 23,765 participants were divided into four groups according to the AISI quartile level. The association between AISI and cardiovascular mortality in patients with HTN was assessed by survival curves and Cox regression analyses based on NHANES recommended weights. Results High levels of AISI were significantly associated with cardiovascular mortality in patients with HTN. After full adjustment for confounders, there was no significant difference in the risk of cardiovascular mortality in Q2 and Q3 compared to Q1, while Q4 (HR: 1.91, 95% CI: 1.42–2.58; P < 0.001) had a higher risk of cardiovascular mortality compared to Q1. Results remained similar in subgroup analyses stratified by age (P for interaction = 0.568), gender (P for interaction = 0.059), and obesity (P for interaction = 0.289). Conclusions In adults with HTN, elevated AISI levels are significantly associated with an increased risk of cardiovascular mortality and may serve as an early warning parameter for poor prognosis.

[1]  Mohammad Reza Aslani,et al.  Aggregate index of systemic inflammation (AISI) in admission as a reliable predictor of mortality in COPD patients with COVID-19 , 2023, BMC Pulmonary Medicine.

[2]  Abdurrahman Akyüz,et al.  Systemic Immune-Inflammation Index: A Novel Predictor for Non-dipper Hypertension , 2022, Cureus.

[3]  S. Carugo,et al.  Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction , 2022, BMC Cardiovascular Disorders.

[4]  A. Mangoni,et al.  The Aggregate Index of Systemic Inflammation (AISI): A Novel Prognostic Biomarker in Idiopathic Pulmonary Fibrosis , 2021, Journal of clinical medicine.

[5]  Gretchen A. Stevens,et al.  Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants , 2021, The Lancet.

[6]  N. Emlek,et al.  Could the systemic immune-inflammation index be a predictor to estimate cerebrovascular events in hypertensive patients? , 2021, Blood pressure monitoring.

[7]  J. V. Van Beusecum,et al.  Hypertension: Do Inflammation and Immunity Hold the Key to Solving this Epidemic? , 2021, Circulation research.

[8]  B. Joe,et al.  Innate Immune Cells and Hypertension: Neutrophils and Neutrophil Extracellular Traps (NETs). , 2021, Comprehensive Physiology.

[9]  A. Mangoni,et al.  Blood Cell Count Derived Inflammation Indexes in Patients with Idiopathic Pulmonary Fibrosis , 2020, Lung.

[10]  A. Galrinho,et al.  C-reactive protein reduction with sacubitril-valsartan treatment in heart failure patients. , 2020, American journal of cardiovascular disease.

[11]  M. Banach,et al.  Clinical approach to the inflammatory etiology of cardiovascular diseases , 2020, Pharmacological Research.

[12]  L. Maier,et al.  Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation. , 2020, Cardiovascular research.

[13]  Mohammad Hosein Farzaei,et al.  Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, Lancet.

[14]  Mohammad Hossein Khosravi,et al.  Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, Lancet.

[15]  I. Tzoulaki,et al.  Genetically Determined Platelet Count and Risk of Cardiovascular Disease , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[16]  P. Wenzel.  Monocytes as immune targets in arterial hypertension , 2018, British journal of pharmacology.

[17]  D. Harrison,et al.  The immunology of hypertension , 2018, The Journal of experimental medicine.

[18]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[19]  M. Nybo,et al.  Platelet count is associated with cardiovascular disease, cancer and mortality: A population-based cohort study. , 2016, Thrombosis research.

[20]  R. Sacco,et al.  C-reactive protein is associated with disability independently of vascular events: the Northern Manhattan Study , 2016, Age and ageing.

[21]  E. Schiffrin,et al.  Role of Inflammation and Immunity in Hypertension: Recent Epidemiological, Laboratory, and Clinical Evidence , 2016, Current Hypertension Reports.

[22]  Jiang He,et al.  Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. , 2015, Circulation.

[23]  K. Peter,et al.  Obligatory Role for B Cells in the Development of Angiotensin II–Dependent Hypertension , 2015, Hypertension.

[24]  D. Harrison,et al.  Inflammation, immunity, and hypertensive end-organ damage. , 2015, Circulation research.

[25]  D. Harrison,et al.  DC isoketal-modified proteins activate T cells and promote hypertension. , 2014, The Journal of clinical investigation.

[26]  S. Taddei,et al.  Impact of inflammation on vascular disease in hypertension. , 2014, Maturitas.

[27]  K. Odunsi,et al.  Effect of cell-free ascites containing mitochondrial DNA (mtDNA) from ovarian cancer (OC) patients on human neutrophils and neutrophil extracellular traps (NETs). , 2014 .

[28]  D. Wagner,et al.  Thrombosis: tangled up in NETs. , 2014, Blood.

[29]  S. Douma,et al.  Nitric oxide dysfunction in vascular endothelium and platelets: role in essential hypertension , 2009, Journal of hypertension.

[30]  M. Chatterjee,et al.  Augmented nitric oxide generation in neutrophils: Oxidative and pro-inflammatory implications in hypertension , 2009, Free radical research.

[31]  D. Harrison,et al.  Role of the T cell in the genesis of angiotensin II–induced hypertension and vascular dysfunction , 2007, The Journal of experimental medicine.

[32]  E. Paffen,et al.  C-reactive protein in atherosclerosis: A causal factor? , 2006, Cardiovascular research.

[33]  D. Behm,et al.  Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: role of systemic blood pressure and endothelial protection. , 2005, Cardiovascular research.

[34]  Ernesto L. Schiffrin,et al.  Vascular Remodeling in Hypertension: Roles of Apoptosis, Inflammation, and Fibrosis , 2001, Hypertension.

[35]  G. Pellegrini,et al.  P-selectin induces the expression of tissue factor on monocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  B. Singh,et al.  Platelets in essential hypertension. , 1993, Thrombosis research.

[37]  J. Erikssen,et al.  Blood Platelet Count and Function Are Related to Total and Cardiovascular Death in Apparently Healthy Men , 1991, Circulation.

[38]  J. Wardle,et al.  Sleep and nighttime energy consumption in early childhood: a population‐based cohort study , 2015, Pediatric obesity.

[39]  Jian‐Jun Li,et al.  Inflammation may be a bridge connecting hypertension and atherosclerosis. , 2005, Medical hypotheses.

[40]  R. Sacco,et al.  The Northern Manhattan Study , 2004 .

[41]  H. Iwao,et al.  [Vascular remodeling]. , 2000, Nihon rinsho. Japanese journal of clinical medicine.